This includes those who: Have heart disease, kidney problems, or overweight Want to avoid weight gain or low blood sugar from other diabetes medicines People with overweight or obesity, including: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher and at least one weight-related health problem (such as high blood pressure or sleep apnea) Adults who have not met weight-loss goals with lifestyle changes alone Adolescents with obesity who qualify for certain GLP-1 medications Who should not receive GLP-1 medications
Direct and Metabolite Effects: While direct GLP-1R expression on -cells is low, degradation products of GLP-1, such as GLP-1(9-36) , may also inhibit glucagon secretion by activating inhibitory G proteins (Gi/o) and modulating calcium channels (Zheng et al., 2024)
CMS announced on April 21 st that they would extend the timeline for the temporary GLP-1 Bridge model through the end of December 2027, providing 18 months of coverage
Specially, many ask about potential side effects and how to reduce or counteract them, he adds, as well as what happens after quitting one of these meds